A Study of the Feasibility of Using the Dietary Supplement "ARTNEO" in Patients With Osteoathritis

Inclusion Criteria: 1. Voluntarily signed informed consent to participate in the study; 2. Men and women in postmenopause, aged 40-75 years, capable of independent movement, BMI 18-30 kg/m2; 3. Verified primary gonarthrosis according to the American College of Rheumatology criteria at least 6 months before enrollment in the study (in the presence of pain in the knee joint and radiological signs of gonarthrosis in combination with one of the following signs: crepitus in the joint or morning stiffness in the joint for less than 30 min); 4. II-III radiological stage of gonarthrosis according to the Kellgren-Lawrence classification with a predominant lesion of the medial tibiofemoral area of the knee joint; 5. Severity of pain in the assessed knee joint at the time of the screening visit from 40 or more on 100-mm VAS while walking; 6. Ability to understand the rules of the study, willingness to follow them; 7. Willingness to limit the diet (soy, avocado, passion fruit, pineapple, turmeric, linseed, rapeseed, soybean oils, chia seeds, walnuts, decoction of willow bark, pine, wormwood, L-carnitine, etc. should be excluded); 8. Consent of the men during the study and within 30 days after its completion to use the methods of contraception described in the protocol of this study. Exclusion Criteria: 1. Individual intolerance to the active or excipients of the ARTNEO® dietary supplement (undenatured type II collagen + methylsulfonylmethane + Boswellia serrata extract + vitamin C + Vitamin D3), placebo and the "rescue" drug ibuprofen; 2. Intolerance to eggs, poultry, shellfish; 3. History of trauma or surgery on the target knee joint (other than diagnostic arthroscopy more than 60 days old at study entry), expected surgery (within 6 months following inclusion); 4. Coronary artery bypass grafting in medical history; 5. Diseases, the presence of which, from the point of view of the research physician, puts the patient's health at risk in case of participation in the study or potentially complicates the interpretation of the results of the study (may affect the assessment of endpoints): * Known or suspected malignancy at the time of screening or in the previous 2 years, other than completely healed skin cancer in situ; * History of gouty arthritis; * Malabsorption syndrome, celiac disease, short bowel syndrome, intestinal lymphangiectasia; * Peptic ulcer of the stomach and duodenum (in the acute phase or in the acute stage), gastrointestinal bleeding, Crohn's disease, u…